ALDX - CIK 0001341235
Aldeyra Therapeutics, Inc. trades as ALDX. This page tracks Aldeyra Therapeutics, Inc. through 630 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-01 |
| Annual report to shareholders | ARS | 2026-04-27 |
| Proxy materials | DEFA14A | 2026-04-27 |
| Proxy statement | DEF 14A | 2026-04-27 |
| Major company event | 8-K | 2026-04-20 |
| Major company event | 8-K | 2026-04-01 |
The largest companies sharing Aldeyra Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
In its latest fiscal year Aldeyra Therapeutics, Inc. reported a net loss of $33.85M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.